Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies

Abstract

Platelet activation has been suggested to play a crucial role in the pathogenesis of haemostatic disorders in antiphospholipid syndrome (APS). In 16 patients with primary APS (PAPS) we investigated by flow cytometry the presence of circulating activated platelets as defined by the surface expression of activation-dependent glycoproteins CD62 and CD63. In addition, the relationships among activated platelets, thrombocytopenia, antiphospholipid antibodies (aPL) and platelet associated IgG (PalgG) were evaluated.

Compared to normal subjects CD62, but not CD63 expression, was found significantly increased in patients. All thrombocytopenic subjects showed a percentage of CD62 expressing platelets above the cut off. In thrombocytopenics a significantly increased percentage of CD62 and higher levels of aCL IgG were found compared to PAPS patients with normal platelet count. No correlation was found between activated platelets and both lupus anticoagulant antibodies and PalgG.

Our data demonstrate that circulating activated platelets are detectable by flow cytometry in the majority of PAPS patients and suggest the existence of a relationship among activated platelets, thrombocytopenia and aPL levels.

Keywords

flow-cytometry platelet activation antiphospholipid syndrome anticardiolipin antibodies thrombocytopenia

Get full access to this article

View all access options for this article.

References

Harris EN , Baguley E. , Hasherson RA , Hughes Grv. Clinical and serological features of the antiphospholipid syndrome. Br J Rheumatol 1987; 26: 19—21.

Vela P. , Batlle E. , Salas E. , Marco P. Primary antiphospholipid syndrome and osteonecrosis. Clin Exp Rheumatol 1991; 9: 545-546.

Hugson MD et al. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kid Dis 1992; 20: 150-158.

Luchi M. , Asherson RA , Lahita RG Primary idiopathic pulmonary hypertension complicated by pulmonary arterial thrombosis. Arthritis Rheum 1992; 35: 700-705.

Aron AL , Gharavi AE , Shoefeld Y. Mechanisms of action of antiphospholipid antibodies in the antiphospholipid syndrome. Intern Arch Allergy Immunol 1995 ; 106: 8-12.

Zwaal Rfa , Comfurius P. , Bevers EM Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Bioch Biophys Acta 1992; 1180: 1-8.

Bevers EM et al. Lupus Anticoagulant IgG's (LA) are not directed to phospholipids only but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991; 66: 629—632.

Galli M. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990 ; 335: 1544-1547.

Galli M. et al. Anticoagulant activity of anticardiolipin antibodies is mediated by β2-glycoprotein I. Thromb Haemostas 1992; 68: 297-300.

10.

Galli M. et al. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 466-472.

11.

Shi W. , Chong BH , Chesterman CN β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 1255-1262.

12.

Vazquez-Mellado J. , Llorente L. , Richaud-Patin Y. , Alarcon-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding of β2-glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun 1994; 7: 335-348.

13.

Brighton TA , Chesterman CN Antiphospholipid antibodies and thrombosis. In: Meade TW (ed). Clinical Haematology: Thrombophylia, Bailliere Tindall WB , Saunders Co. Ltd , London, UK. 1994, pp 541-557.

14.

Shattil SJ , Cunningham M. , Hoxie JA Detecton of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315.

15.

Abrams CS , Ellison N. , Budzynski AZ Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-138.

16.

McEver RP Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood cells 1990; 16: 73-83.

17.

Nieuwenhuis K. et al. Studies with a monoclonal antibodies against activated platelets. Evidence that a secreted 53 000 molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in circulation. Blood 1987; 70: 838-845.

18.

Metzelaar MJ , Sixma J. , Nieuwenhuis K. Detection of platelet activation using activation specific monoclonal antibodies. Blood cells 1990; 16: 85—96.

19.

Corash L. Measurement of platelet activation by fluorescence-activated flow cytometry . Blood cells 1990; 16: 97-108.

20.

Abrams C. , Shattil SJ Immunological detection of activated platelets in clinical disorders. Thromb Haemostas i 1991; 5: 467-473.

21.

Wehmeier A. et al. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991; 61: 271-278.

22.

Metzelaar MJ , Korteweg J. , Sixma JJ , Nieuwenhuis K. Comparison of platelet membrane markers for the detection of platelets activation in vitro and during platelets storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993; 121: 579-587.

23.

Tschoepe D. et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.

24.

Gralnick HR et al. Activated platelets in paroxysmal nocturnal hemoglobinuria. Br J Haematol 1995; 91: 697-702.

25.

Out JH et al. Antibodies to platelets in patients with anti-phospholipid antibodies . Blood, 1991; 77: 2655-2659.

26.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1271.

27.

Alarcon Segovia D. Antiphospholipid syndrome within systemic lupus erithematosus. Lupus 1994; 3(4): 289-291.

28.

Harris EN et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in SLE. Lancet 1983; 3: 1211-1214.

29.

Tincani A. et al. Antiphospholipid and antimithocondrial type M5 antibodies in SLE. Ex Rheumatol 1988; 3: 321-325.

30.

McEver RP , Martin NM A monoclonal antibody to a membrane glycoprotein binds only to activated platelets . J Biol Chem 1984; 259: 9799-9804.

31.

George JN , Pickett EB , Saucermann S. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery . J Clin Invest 1986; 78: 340-345.

32.

George JN , Pickett EB , Heinz R. Platelet membrane gylcoprotein changes during the preparation and storage of platelets concentrates. Transfusion 1988 28: 123-126.

33.

Ault KA , Mitchell J. Analysis of platelets by flow cytometry. Methods Cell Biol 1994; 42: 275-295.

34.

Arvieux J. et al. Lupus-like anticoagulant properties of murine monoclonal antibodies to β2-glycoprotein I. Haematol 1992; 81: 568-573.

35.

Branch DW , Rodgers GM

Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obs and

Gynecol 1993; 168: 206-210.

36.

Yuh-Ling L. , Cheng-Teh W. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80: 3135-3143.